Progression of Peyronie's Disease during Tamoxifen Treatment / 대한남성과학회지
Korean Journal of Andrology
;
: 52-56, 2012.
Article
Dans Anglais
| WPRIM
| ID: wpr-20199
ABSTRACT
PURPOSE:
Medical treatment of Peyronie's disease with tamoxifen has been initially proposed as acting upon the early phase of the disease. As recent reports show no significant benefit of tamoxifen, we review the long term results of tamoxifen treatment of Peyronie's disease. MATERIALS ANDMETHODS:
Time to progression during tamoxifen treatment of patients showing acute disease and chronic disease was compared. The acute phase was identified by pain during erection. Progression was defined as enlargement of plaque size or appearance of calcification.RESULTS:
The average treatment duration was 15.9+/-13.8 months (range 3 to 48 months). The median time to progression was 7 months for acute patients and 20 months for chronic patients. Eighty percent of patients in the acute phase showed relief of pain; however, overall progression was 72.1% (78.0% for acute, 66.7% for chronic). Patient history, comorbidities, serum testosterone or initial plaque characteristics, and severity of curvature were not predictive of disease progression.CONCLUSIONS:
Tamoxifen showed no significant benefit in slowing the progression of Peyronie's disease in the acute phase over the chronic phase. Peyronie's disease continued to progress, though at a dampened rate for patient's in the chronic phase.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Induration plastique des corps caverneux du pénis
/
Tamoxifène
/
Testostérone
/
Comorbidité
/
Maladie aigüe
/
Maladie chronique
Type d'étude:
Étude pronostique
Limites du sujet:
Humains
/
Mâle
langue:
Anglais
Texte intégral:
Korean Journal of Andrology
Année:
2012
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS